Drug Trial Radar · NCT03794440
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Last checked: Nov 19, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
595
Actual
Start
Feb 11, 2019
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label,Multi-center Study. The primary endpoint is overall survival.
Conditions
- Hepatocellular Carcinoma
Interventions
SintilimabDrug
200mg IV d1, Q3W
IBI305Drug
15mg/kg IV d1, Q3W
SorafenibDrug
400mg PO BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: up to 24 months after randomization
- Progression-free survival (PFS)Time frame: up to 24 months after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.